JP7851856B2 - 疾患の治療のためのファルネソイドｘ受容体アゴニスト - Google Patents

疾患の治療のためのファルネソイドｘ受容体アゴニスト

Info

Publication number
JP7851856B2
JP7851856B2 JP2022555913A JP2022555913A JP7851856B2 JP 7851856 B2 JP7851856 B2 JP 7851856B2 JP 2022555913 A JP2022555913 A JP 2022555913A JP 2022555913 A JP2022555913 A JP 2022555913A JP 7851856 B2 JP7851856 B2 JP 7851856B2
Authority
JP
Japan
Prior art keywords
compound
disease
pharmaceutically acceptable
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022555913A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518397A5 (enExample
JP2023518397A (ja
Inventor
ソン，ケネス
チェン，ヒューバート
ワーグナー，ブランディー
ディー． スミス，ニコラス
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2023518397A publication Critical patent/JP2023518397A/ja
Publication of JP2023518397A5 publication Critical patent/JP2023518397A5/ja
Application granted granted Critical
Publication of JP7851856B2 publication Critical patent/JP7851856B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022555913A 2020-03-18 2021-03-17 疾患の治療のためのファルネソイドｘ受容体アゴニスト Active JP7851856B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062991292P 2020-03-18 2020-03-18
US62/991,292 2020-03-18
US202063069667P 2020-08-24 2020-08-24
US63/069,667 2020-08-24
US202163140735P 2021-01-22 2021-01-22
US63/140,735 2021-01-22
PCT/US2021/022786 WO2021188688A1 (en) 2020-03-18 2021-03-17 Farnesoid x receptor agonists for the treatment of disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026066715A Division JP2026133383A (ja) 2020-03-18 2026-04-15 疾患の治療のためのファルネソイドｘ受容体アゴニスト

Publications (3)

Publication Number Publication Date
JP2023518397A JP2023518397A (ja) 2023-05-01
JP2023518397A5 JP2023518397A5 (enExample) 2024-03-29
JP7851856B2 true JP7851856B2 (ja) 2026-04-27

Family

ID=77771857

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022555913A Active JP7851856B2 (ja) 2020-03-18 2021-03-17 疾患の治療のためのファルネソイドｘ受容体アゴニスト

Country Status (12)

Country Link
US (1) US20230131804A1 (enExample)
EP (1) EP4121048A4 (enExample)
JP (1) JP7851856B2 (enExample)
KR (1) KR20220154801A (enExample)
CN (4) CN120732855A (enExample)
AU (1) AU2021240001A1 (enExample)
BR (1) BR112022018651A2 (enExample)
CA (1) CA3172205A1 (enExample)
IL (1) IL296539A (enExample)
MX (1) MX2022011579A (enExample)
TW (1) TWI895384B (enExample)
WO (1) WO2021188688A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3852748B1 (en) 2018-09-18 2025-09-03 Eli Lilly and Company Farnesoid x receptor agonists and uses thereof
CN120227340A (zh) 2020-03-18 2025-07-01 伊莱利利公司 法尼醇x受体激动剂的制剂
JP7664278B2 (ja) * 2020-03-18 2025-04-17 オルガノボ，インク． ファルネソイドｘ受容体アゴニストの結晶質形態
CN117018000B (zh) * 2023-08-29 2025-01-28 东莞市东南部中心医院(东莞市东南部中医医疗服务中心) 4-胆甾烯-3-酮在制备预防或治疗炎症性肠病药物中的应用
WO2026149323A1 (en) * 2025-01-07 2026-07-16 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods of using mitochondrial uncouplers and glp-1 receptor agonists
CN120837611B (zh) * 2025-09-22 2025-12-16 吉林大学 一种经鼻给药的司美格鲁肽制剂及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170166A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2018170182A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
JP2018536015A (ja) 2015-09-16 2018-12-06 メタクリン，インク． ファルネソイドｘ受容体アゴニストとその使用
WO2020061113A1 (en) 2018-09-18 2020-03-26 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) * 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
AU2016233579A1 (en) * 2015-03-13 2017-10-12 Salk Institute For Biological Studies Treating latent autoimmune diabetes of adults with farnesoid X receptor agonists to activate intestinal receptors
WO2017049176A1 (en) * 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
EP3350166A4 (en) * 2015-09-16 2019-05-01 Metacrine, Inc. FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF
WO2018170173A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018536015A (ja) 2015-09-16 2018-12-06 メタクリン，インク． ファルネソイドｘ受容体アゴニストとその使用
WO2018170166A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2018170182A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2020061113A1 (en) 2018-09-18 2020-03-26 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof

Also Published As

Publication number Publication date
IL296539A (en) 2022-11-01
CN120732854A (zh) 2025-10-03
EP4121048A4 (en) 2024-06-12
US20230131804A1 (en) 2023-04-27
EP4121048A1 (en) 2023-01-25
CA3172205A1 (en) 2021-09-23
JP2023518397A (ja) 2023-05-01
KR20220154801A (ko) 2022-11-22
BR112022018651A2 (pt) 2022-11-29
AU2021240001A1 (en) 2022-10-13
CN115666559A (zh) 2023-01-31
WO2021188688A1 (en) 2021-09-23
TWI895384B (zh) 2025-09-01
CN120732855A (zh) 2025-10-03
CN120732856A (zh) 2025-10-03
TW202143961A (zh) 2021-12-01
MX2022011579A (es) 2022-11-30

Similar Documents

Publication Publication Date Title
US20220323414A1 (en) Farnesoid x receptor agonists for the treatment of disease
TWI895384B (zh) 用於治療疾病之法尼醇x受體促效劑
Lee et al. Inflammatory and fibrotic mechanisms in NAFLD—Implications for new treatment strategies
JP7313405B2 (ja) 線維症の治療
EP3585374B1 (en) Combination of a ppar agonist with a fxr agonist
TW202114672A (zh) 使用fxr促效劑的肝臟疾病之組合治療
US20190175619A1 (en) Treatment of fibrosis, and inhibition of fibrosis in non-alcoholic fatty liver disease patients
Sinakos et al. Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis
JP2024096989A (ja) 腎障害の処置で使用するための化合物
WO2021188690A1 (en) Farnesoid x receptor agonists for the treatment of disease
HK40131843A (en) Farnesoid x receptor agonists for the treatment of diseases
HK40131844A (en) Farnesoid x receptor agonists for the treatment of disease
CN114401745A (zh) 包含fxr激动剂的治疗
Abburi et al. Glucagon-like peptide-1 receptor analogues and beyond: Emerging obesity pharmacotherapies
US20250332176A1 (en) Treatment for fibrosis and inhibition of fibrosis
US20220362263A1 (en) Treatment for fibrosis and inhibition of fibrosis
Maroni¹ et al. The pathophysiology of gut-liver
Magdaleno et al. Animal Models When Examining the Gut-Liver Axis
Sumida et al. An eBook on Diabetes
JP2019537607A (ja) 非アルコール性脂肪性肝疾患の患者における線維化の抑制
Lesley et al. Present and future challenges in Type 2 diabetes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221129

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221219

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250421

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260415

R150 Certificate of patent or registration of utility model

Ref document number: 7851856

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150